Incretin-Based Drugs May Reduce Risk of Dementia in Patients With Type 2 Diabetes
Results from a population-based study published by investigators in Drug Safety demonstrate that dipeptidyl peptidase 4 (DPP-4) inhibitors and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) could reduce the risk…